SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences’ arm gets tentative approval for Canagliflozin, Metformin Hydrochloride Tablets

20 Feb 2023 Evaluate

Zydus Lifesciences’ subsidiary -- Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the United States Food and Drug Administration (USFDA) for Canagliflozin and Metformin Hydrochloride Tablets, 50 mg/500 mg, 50 mg/1,000 mg, 150 mg/500 mg, and 150 mg/1,000 mg (USRLD: Invokamet Tablets).

Canagliflozin and metformin combination product is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on a regimen containing metformin or canagliflozin or in patients already being treated with both canagliflozin and metformin. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.

Canagliflozin and Metformin Hydrochloride Tablets had annual sales of $49.4 million in the United States (IQVIA MAT December 2022). The group now has 344 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

938.75 -3.80 (-0.40%)
20-Apr-2026 11:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.15
Dr. Reddys Lab 1236.65
Cipla 1236.45
Zydus Lifesciences 938.75
Lupin 2328.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×